Diluent for inflammation detection, kit and application

By preparing diluents and kits suitable for whole blood, combined with direct chemiluminescence, the problem of whole blood detection in the existing technology is solved, and the detection of inflammatory markers with high sensitivity and accuracy is achieved, which simplifies operation and reduces costs. for clinical application.

CN119064569APending Publication Date: 2024-12-03BAODING ABIORES CHIP CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411278319.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing inflammatory marker assay kits are mainly used for serum and plasma detection, making it difficult to detect whole blood samples other than serum and plasma with simple, high sensitivity and high accuracy, and are costly, complex in operation, and limited applicability.

Method used

Prepare a diluent including magnetic bead diluent, acridinyl ester diluent and calibration product diluent, combined with direct chemiluminescence method to develop a kit suitable for whole blood detection, which improves the formulation and process by optimizing the formulation and process. Kits are sensitive, accurate and stable, and reduce costs.

Benefits of technology

It realizes high sensitivity and accuracy detection of whole blood, simplifies the operation process, reduces material costs, is suitable for clinical applications, and has consistent and reliable test results, and is suitable for early inflammatory diagnosis and treatment evaluation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119064569A_ABST
    Figure CN119064569A_ABST
Patent Text Reader

Abstract

The invention discloses a diluent for inflammation detection, a kit and application, and belongs to the field of medical diagnosis. The invention discloses a kit for detecting inflammation by a direct chemiluminescence method. The kit comprises a magnetic bead diluent, an acridinium ester diluent, a calibrator diluent, a concentrated cleaning solution, a substrate A and a substrate B, the kit is used for detecting inflammatory markers such as serum amyloid protein A (SAA), full-scale C-reactive protein (CRP), interleukin 6 (IL-6) and procalcitonin (PCT), has the advantages of high sensitivity and accuracy, wide linear range, good repeatability and stability, good clinical sample correlation, low cost, simplicity and convenience in operation, high accuracy and the like, and is easy for mass production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical diagnosis, and in particular to a diluent, a kit and applications for inflammation detection. Background Art

[0002] Inflammation is a physiological response of the human body. It is a protective response of the body to infection by pathogens (such as bacteria, viruses, etc.), trauma or other diseases. It aims to eliminate the stimulus, remove damaged tissues, and initiate the repair process. The serum amyloid A (SAA) assay kit, the full-scale C-reactive protein (CRP) assay kit, the interleukin 6 (IL-6) assay kit, and the procalcitonin (PCT) assay kit are all used to quantitatively determine the content of inflammatory markers in human serum, plasma and whole blood samples in vitro to determine whether there is an inflammatory response. As a new generation of inflammatory infection indicators, SAA makes up for the deficiency of currently commonly used inflammatory markers in indicating viral infection. Its combination with CRP can be used for early identification of viral and bacterial infections; the combined detection of PCT and IL-6 can avoid the error of a single indicator in judging the infection category, and has a stronger effect on the diagnosis and tracking of sepsis. The combined use of the four items can improve the early diagnosis rate of infection, help the clinic determine the treatment plan for patients in a timely manner, and thus improve the success rate of patient treatment, which has important clinical application value.

[0003] Common detection methods used in the above assay kits include direct chemiluminescence, enzymatic chemiluminescence, and fluorescent immunoassay. The principle of direct chemiluminescence is to directly label antibodies with acridinium esters, and after an immune reaction with the corresponding antigen in the sample to be tested, a solid-phase coated antibody-antigen to be tested acridinium ester-labeled antibody complex is formed. At this time, only an oxidant (H2O2) and NaOH need to be added to create an alkaline environment, and acridinium esters can decompose and emit light without the need for a catalyst. The photon energy generated per unit time is received and recorded by the light collector and photomultiplier tube. The integral of this part of light is proportional to the amount of the antigen to be tested, and the content of the antigen to be tested can be calculated from the standard curve.

[0004] The sample types detected by conventional inflammatory marker assay kits on the market are serum and plasma. It is necessary to develop an assay kit that is easy to operate, highly sensitive and accurate, and can detect whole blood in addition to serum and plasma. The detection method is to test diluted whole blood. Summary of the invention

[0005] The purpose of the present invention is to provide a diluent, a kit and an application for inflammation detection to solve the problems existing in the above-mentioned prior art. The diluent and the kit prepared by the present invention are used for inflammation detection, and have the advantages of high sensitivity and accuracy, wide linear range, good repeatability and stability, good clinical sample correlation, low cost, simple operation, high accuracy, etc., and are easy to mass produce.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] The invention provides a diluent for inflammation detection, comprising a magnetic bead diluent, an acridinium ester diluent and a calibration substance diluent; wherein the magnetic bead diluent comprises the following components: NaH2PO4·2H2O 1.5-2.3 g / L, Na2HPO4·12H2O 1.1-1.5 g / L, sodium chloride 8.0-9.0 g / L, alkoxy polyethylene hydroxyethanol 0.4-1.2 mL / L, sorbitan sesquioleate 0.7-1.4 mL / L, casein 1.4-1.8 g / L, glycine 10.0-12.0 g / L, tryptone 5.3-6.0 g / L and Proclin300 1.2-2.5 mL / L;

[0008] The acridinium ester diluent comprises the following components: NaH2PO4·2H2O 3.6-3.9 g / L, Na2HPO4·12H2O 2.2-2.5 g / L, sodium chloride 6.9-7.0 g / L, glycerol 0.9-1.0 mL / L, sorbitol oleate 2.3-2.5 mL / L, sucrose 0.7-0.9 g / L, Tween-80 1.3-1.5 mL / L, tryptone 5.2-5.6 g / L and Proclin 300 1.2-2.5 mL / L;

[0009] The calibration diluent comprises the following components: NaH2PO4·2H2O 1.5-2.2 g / L, Na2HPO4·12H2O 1.3-1.5 g / L, sodium chloride 5.3-5.7 g / L, Triton X-100 0.6-1.2 mL / L, D-sorbitol 0.4-1.6 g / L, sucrose 0.8-1.5 g / L and Proclin 300 1.2-2.5 mL / L.

[0010] The present invention also provides a method for preparing the diluent, comprising preparing a magnetic bead diluent, an acridinium ester diluent and a calibrant diluent respectively by the following method:

[0011] (1) The method for preparing the magnetic bead diluent comprises the following steps:

[0012] According to the formula of the magnetic bead diluent, weigh each component for later use;

[0013] Add NaH2PO4·2H2O, Na2HPO4·12H2O and sodium chloride to purified water in sequence, stir to fully dissolve, and then adjust the pH to 7.2-7.5 to obtain an intermediate solution;

[0014] Adding alkoxy polyethylene hydroxyethanol, sorbitan sesquioleate, casein, Proclin 300, glycine and tryptone to the intermediate solution in sequence and mixing them evenly;

[0015] Dilute to volume with purified water to obtain the magnetic bead dilution solution;

[0016] (2) The preparation method of the acridinium ester dilution comprises the following steps:

[0017] According to the formula of the acridinium ester diluent, weigh each component for later use;

[0018] Add NaH2PO4·2H2O, Na2HPO4·12H2O and sodium chloride to purified water in sequence, stir to fully dissolve, and then adjust the pH to 7.5-7.8 to obtain an intermediate solution;

[0019] Add glycerol, sorbitan oleate, sucrose, Tween-80, tryptone and Proclin 300 to the intermediate solution in sequence and mix well;

[0020] Dilute to volume with purified water to obtain the acridinium ester dilution solution;

[0021] In the above formula, sorbitan oleate and Tween-80 are surfactants, which can increase the stability of the solution when used in conjunction with each other in the reagent. Glycerol, trypsin and sucrose are protein protectants, which can increase the stability of the antibody when used in conjunction with each other in the reagent. Various components in the reagent interact with each other, making the acridinium ester dilution solution more stable.

[0022] (3) The preparation method of the calibration dilution comprises the following steps:

[0023] According to the formula of the calibration diluent, weigh each component for later use;

[0024] To purified water for in vitro diagnostic reagents, NaH2PO4·2H2O, Na2HPO4·12H2O and sodium chloride were sequentially added, stirred to fully dissolve, and then the pH was adjusted to 7.5-7.8 to obtain an intermediate solution;

[0025] Adding Triton X-100, D-sorbitol, sucrose and Proclin 300 to the intermediate solution in sequence and mixing well;

[0026] The in vitro diagnostic reagent is diluted to volume with purified water to obtain the calibrator dilution solution.

[0027] The present invention also provides an application of the diluent in preparing a kit for detecting inflammation by direct chemiluminescence method.

[0028] Preferably, the kit for detecting inflammation by direct chemiluminescence is a kit for detecting inflammatory markers by direct chemiluminescence, and the inflammatory markers include serum amyloid A, full-range C-reactive protein, interleukin 6 and procalcitonin.

[0029] The invention also provides a kit for detecting inflammation by direct chemiluminescence method, comprising the diluent.

[0030] Preferably, the diluent is used in the form of a working solution when in use, wherein the magnetic bead diluent is prepared by preparing the coated magnetic bead-coated antibody and the magnetic bead diluent at a volume ratio of 1:25, 1:50 or 1:100 to obtain a magnetic bead working solution; the acridinium ester diluent is prepared by preparing the acridinium ester diluent and the acridinium ester-labeled antibody at a volume ratio of 1:100, 1:200 or 1:400 to obtain an acridinium ester working solution; the calibrator diluent is prepared by diluting the calibrator diluent with the antigen according to a concentration in the linear range of [0.0015-200000] ng / mL to prepare a calibrator working solution.

[0031] Preferably, the kit further comprises a cleaning solution concentrate, substrate A and substrate B. That is, the magnetic bead diluent, acridinium ester diluent, calibrator diluent, cleaning solution concentrate, substrate A and substrate B are assembled to obtain a kit for detecting inflammation by direct chemiluminescence.

[0032] Preferably, the cleaning solution concentrate comprises disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, Tween-20 and Proclin 300; the substrate A is an acidic solution containing H2O2; and the substrate B is an alkaline solution containing Triton X-100.

[0033] The present invention discloses the following technical effects:

[0034] (1) The kit for detecting inflammation by direct chemiluminescence prepared by the present invention has good stability, high accuracy, simple operation, easy sample collection, easy preparation, and saves material costs. It is suitable for promotion and use, and is more suitable for clinical application.

[0035] (2) The detection of inflammatory markers (SAA, CRP, IL-6 and PCT) using the kit prepared by the present invention is simple to operate and fully automatic, and can quickly and accurately detect the substance content within 15 minutes, truly reflecting the progression of the disease and evaluating the treatment effect. In addition, the fully automatic detection is not easily interfered by human operation and external factors, and has high sensitivity, good specificity, and better stability and repeatability.

[0036] (3) Compared with conventional assay kits on the market that detect serum and plasma samples, the inflammation detection kit prepared by the present invention can be used for the detection of whole blood in addition to serum and plasma samples, and the results are consistent, accurate and reliable. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0038] Figure 1 The antigen linearity test result of the kit prepared in Example 1;

[0039] Figure 2 The results are the correlation between the detection of clinical samples using the kit prepared in Example 1 of the present invention and the Roche diagnostic kit and other domestic kits sold in the market. DETAILED DESCRIPTION

[0040] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0041] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0042] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0043] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0044] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0045] Some of the reagents involved in the following examples are shown in Table 1.

[0046] Table 1 Reagents

[0047]

[0048]

[0049]

[0050] Example 1 Preparation of serum amyloid A assay kit (direct chemiluminescence method)

[0051] 1. Prepare magnetic bead working solution

[0052] 1.1 Magnetic bead dilution solution formula

[0053] (1) Magnetic bead dilution solution formula 1:

[0054] NaH2PO4·2H2O 2.0g / L, Na2HPO4·12H2O 1.4g / L, sodium chloride 8.7g / L, alkoxypolyethylene glycol hydroxyethanol 0.5mL / L, sorbitan sesquioleate 1.3mL / L, casein 1.8g / L, glycine 11.0g / L, tryptone 6.0g / L and Proclin3002.2 mL / L.

[0055] (2) Magnetic bead dilution solution formula 2:

[0056] NaH2PO4·2H2O 2.3g / L, Na2HPO4·12H2O 1.2g / L, sodium chloride 8.3g / L, alkoxypolyethylene glycol hydroxyethanol 1.1mL / L, sorbitan sesquioleate 1.0mL / L, casein 1.5g / L, glycine 12.0g / L, tryptone 5.6g / L and Proclin3001.4 mL / L.

[0057] 1.2 Preparation of magnetic bead diluent

[0058] (1) According to the formula of the magnetic bead diluent, weigh each component for later use;

[0059] (2) NaH2PO4·2H2O, Na2HPO4·12H2O, and sodium chloride are sequentially added to purified water for in vitro diagnostic reagents, stirred to fully dissolve, and the pH is adjusted to 7.2-7.5 to obtain an intermediate solution;

[0060] (3) adding alkoxy polyethylene glycol, sorbitan sesquioleate, casein, Proclin 300, glycine, and trypsin to the intermediate solution in sequence and mixing well;

[0061] (4) The volume is fixed with purified water to obtain the magnetic bead dilution solution.

[0062] 1.3 Coating process

[0063] 1) Magnetic bead cleaning:

[0064] Take 100 μL of uniformly dispersed non-agglutinated magnetic bead stock solution (concentration: 100 mg / mL) and add it to a 2mL EP tube, add 1mL of magnetic bead coupling buffer, mix it upside down 10 times to resuspend the magnetic beads, place it in a magnetic separator for 1 minute, discard the supernatant, add 1mL of magnetic bead coupling buffer, mix it upside down 10 times to resuspend the magnetic beads; repeat the above steps 3 times, after the last wash, add 1mL of magnetic bead coupling buffer, mix it upside down 10 times to resuspend the magnetic beads.

[0065] 2) Magnetic bead activation:

[0066] Use magnetic bead coupling liquid to dissolve N-hydroxysuccinimide (NHS) to prepare a 20 mg / mL NHS solution (prepare it before use and use it within 30 minutes after preparation), add 230 μL of 20 mg / mL NHS solution to the above EP tube, and mix it upside down 10 times; use magnetic bead coupling liquid to dissolve 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) to prepare a 10 mg / mL EDC solution (prepare it before use and use it within 30 minutes after preparation), add 100 μL of 10 mg / mL EDC solution to the above EP tube, and mix it upside down 10 times; place it on a mixer to react for 30 minutes at a rate of 50 r / min.

[0067] 3) Cleaning:

[0068] After the above solution was placed in the magnetic separator for 3 minutes, the supernatant was discarded, 1 mL of magnetic bead coupling buffer was added respectively, and the magnetic beads were resuspended by inverting 10 times. After being placed in the magnetic separator for 3 minutes, the supernatant was discarded, and the above steps were repeated 3 times.

[0069] 4) Antibody conjugation:

[0070] Add 100 μg of coating antibody to the above EP tubes, mix them by inverting them 10 times, and then place them on a mixer to react for 5 hours at a rate of 50 r / min.

[0071] 5) Magnetic bead blocking:

[0072] After the above solution is placed in the magnetic separator for 3 minutes, the supernatant is discarded, 1 mL of magnetic bead preservation solution is added, and the magnetic beads are resuspended by inverting 10 times. After placing it in the magnetic separator for 3 minutes, the supernatant is discarded, and the above steps are repeated 3 times. After the final wash, 1 mL of 10% BSA is added and the mixture is placed on a mixer for reaction for 30 minutes at a rate of 50 r / min.

[0073] 6) Magnetic bead cleaning:

[0074] After the above solution was placed in the magnetic separator for 3 minutes, the supernatant was discarded, and 1 mL of magnetic bead storage solution was added to resuspend the magnetic beads. After placing in the magnetic separator for 3 minutes, the supernatant was discarded. The above steps were repeated 3 times, and 1 mL was added after the final wash.

[0075] The coated antibody and magnetic bead diluent are mixed in proportion to obtain the magnetic bead working solution. The possible ratios are (1:25, 1:50 or 1:100, v:v). The final ratio used in this kit is 1:50.

[0076] 1.4 Optimization of components in magnetic bead working solution

[0077] Taking SAA as an example, the correlation of different components in the magnetic bead working solution was determined. The specific formula is shown in Table 2. When the magnetic bead diluent with a complete formula is used, the linearity of the kit is as high as 0.9989, and the correlation is better.

[0078] Table 2 Effect of different components on linearity in SAA kit

[0079]

[0080]

[0081] Note: ① is alkoxy polyethylene glycol. ② is sorbitan sesquioleate. ③ is casein. ④ is glycine. ⑤ is trypsin.

[0082] 2. Preparation of acridinium ester working solution

[0083] 2.1 Acridinium ester dilution solution formula

[0084] (1) Acridinium ester dilution liquid formula 1:

[0085] Components: NaH2PO4·2H2O 3.7 g / L, Na2HPO4·12H2O 2.5 g / L, sodium chloride 7.0 g / L, glycerol 0.9 mL / L, sorbitan oleate 2.5 mL / L, sucrose 0.8 g / L, Tween-80 1.3 mL / L, trypsin 5.5 g / L and Proclin 300 2.5 mL / L.

[0086] (2) Acridinium ester dilution liquid formula 2:

[0087] Components: NaH2PO4·2H2O 3.9 g / L, Na2HPO4·12H2O 2.3 g / L, sodium chloride 6.9 g / L, glycerol 1.0 mL / L, sorbitan oleate 2.3 mL / L, sucrose 0.9 g / L, Tween-80 1.4 mL / L, trypsin 5.3 g / L and Proclin 300 1.8 mL / L.

[0088] 2.2 Preparation of acridinium ester dilution solution

[0089] (1) According to the formula of the acridinium ester dilution solution, weigh each component for later use;

[0090] (2) adding NaH2PO4·2H2O, Na2HPO4·12H2O, and sodium chloride to purified water in sequence, stirring to fully dissolve, and then adjusting the pH to 7.5-7.8 to obtain an intermediate solution;

[0091] (3) adding glycerol, sorbitan oleate, sucrose, Tween-80, tryptone, and Proclin 300 to the intermediate solution in sequence and mixing well;

[0092] (4) Add purified water to make up to volume to obtain an acridinium ester dilution solution.

[0093] 2.3 Acridinium ester labeling

[0094] 1) Dialysis bag pretreatment

[0095] Cut a 12 cm long dialysis bag, first moisten it with purified water for in vitro diagnostic reagents, then use a 1000 μL pipette to draw purified water for in vitro diagnostic reagents, rinse the inside of the dialysis bag 10 times, and soak it in a beaker containing 200 mL of purified water for in vitro diagnostic reagents for later use.

[0096] 2) Acridinium ester dilution

[0097] Wrap the outside of the EP tube with tin foil and mark the information on it. Add 400 μL of acridinium ester labeling buffer. Add 5 μL of acridinium ester solution (concentration 4 mM) to the EP tube and mix it by inverting it 10 times.

[0098] 3) Antibody labeling

[0099] Take 100 μg of antibody and add it to the above 1 EP tube, mix it by inverting it 10 times, and place it on a mixer to react for 50 minutes in the dark at a speed of 50 r / min.

[0100] 4) Acridinium ester quenching

[0101] Use acridinium ester labeling buffer to dissolve lysine to prepare acridinium ester quencher. After the labeling reaction is completed, add 50 μL of acridinium ester quencher respectively, immediately mix with a pipette 10 times, place on a mixer at 50 r / min to mix in the dark, and quench for 30 minutes.

[0102] 5) Purification of Acridinium Ester Labeled Antibodies

[0103] Transfer the acridinium ester-labeled antibody reaction solution to a pretreated and fully soaked dialysis bag, clamp it with a dialysis clamp, and place it in 1L of acridinium ester purification buffer. Replace the acridinium ester purification buffer every 2 hours (when purifying overnight for 10-14 hours, the acridinium ester purification buffer needs to be added to 2L). After 20 hours of purification, before each replacement of the acridinium ester purification buffer, aspirate 1mL of the acridinium ester purification buffer outside the dialysis bag and use a fully automatic chemiluminescence immunoassay to detect the luminescence value.

[0104] 6) Collection

[0105] When the luminescence value of the acridinium ester purification buffer solution is less than 100,000, transfer the liquid in the dialysis bag to a new EP tube, add an equal volume of glycerol, and mix well.

[0106] The labeled antibody and acridinium ester diluent are prepared in proportion to obtain the acridinium ester working solution. The possible preparation ratios are (1:100, 1:200 or 1:400, v:v). The final ratio selected for this kit is 1:200.

[0107] 3. Preparation of Calibrator Working Solution

[0108] 3.1 Calibrator dilution formula

[0109] (1) Calibrator dilution formula 1:

[0110] NaH2PO4·2H2O 1.5g / L, Na2HPO4·12H2O 1.5g / L, sodium chloride 5.4g / L, Triton X-100 1.1mL / L, D-sorbitol 0.8g / L, sucrose 0.9g / L and Proclin300 2.2 mL / L.

[0111] (2) Calibrator dilution formula 2:

[0112] NaH2PO4·2H2O 2.1g / L, Na2HPO4·12H2O 1.4g / L, sodium chloride 5.6g / L, Triton X-100 0.7mL / L, D-sorbitol 1.3g / L, sucrose 1.3g / L and Proclin 300 1.4 mL / L.

[0113] 3.2 Preparation of Calibrator Dilutions

[0114] (1) According to the formula of the calibration diluent, weigh each component for later use;

[0115] (2) adding NaH2PO4·2H2O, Na2HPO4·12H2O, and sodium chloride to purified water in sequence, stirring to fully dissolve, and then adjusting the pH to 7.5-7.8 to obtain an intermediate solution;

[0116] (3) adding Triton X-100, D-sorbitol, sucrose and Proclin 300 to the intermediate solution in sequence and mixing well;

[0117] (4) Dilute to volume with purified water to obtain the calibration dilution solution.

[0118] The antigen was added into the calibrator diluent at the concentration of 0.50, 2.00, 10.00, 50.00 and 200.00 μg / mL to obtain the calibrator working solution.

[0119] 4. Preparation of other reagents

[0120] The cleaning solution concentrate, substrate A, substrate B, reagents and buffers used in the magnetic bead coating process include: magnetic bead coupling buffer, NHS, EDC, 10% BSA, magnetic bead preservation solution, acridinium ester labeling buffer, quencher. The formula and preparation method of the reagents are as follows.

[0121] 4.1 Standard formula of cleaning fluid concentrate: based on 10L base volume, 40g disodium hydrogen phosphate, 229.9g sodium dihydrogen phosphate, 1800g sodium chloride, 90mL S7 surfactant and 12mL Proclin 300.

[0122] Preparation method of cleaning solution concentrate: Add 8L of purified water to the preparation barrel, accurately weigh disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, S7 surfactant and Proclin300, add them to the preparation barrel, stir at a uniform speed, and make up to 10L after full dissolution, and store at 2℃ away from light for later use.

[0123] 4.2 Standard formula of substrate solution A: based on 1000mL base volume: 3.45mL of concentrated nitric acid, 16.45g of hydrogen peroxide.

[0124] Preparation method of substrate solution A: Add 800 mL of purified water for in vitro diagnostic reagents into the preparation bucket, accurately weigh concentrated nitric acid and hydrogen peroxide, add them to the preparation bucket, stir to fully dissolve, then make up to 1000 mL, and store at 2°C for later use.

[0125] 4.3 Standard formula of substrate solution B: based on 1000 mL standard amount: S7 surfactant 3.2 g, sodium hydroxide 12 g.

[0126] Preparation method of substrate solution B: Add 800 mL of purified water to the preparation bucket, accurately weigh S7 surfactant and sodium hydroxide, add them to the preparation bucket, stir at a uniform speed, and make up to 1000 mL after full dissolution, and store at 2°C away from light for later use.

[0127] 4.4 Standard formula of magnetic bead coupling buffer: according to 1000mL base volume: MES 19.553g, Tween-20 1mL, 4mol / LNaOH 1.25mL, in vitro diagnostic reagent is diluted to 1000mL with purified water.

[0128] Preparation method of magnetic bead coupling buffer: add 800mL of purified water for in vitro diagnostic reagents into the preparation bucket, add MES, Tween-20, and 4mol / LNaOH into the preparation bucket, stir at a uniform speed to fully dissolve them, make up to 1000mL with purified water for in vitro diagnostic reagents, and store at 2℃ for later use.

[0129] 4.5 Standard formula of NHS solution: According to 1mL base volume: NHS 0.02g, magnetic bead coupling buffer is made up to 1mL.

[0130] Preparation method of NHS solution: Add 0.02 g of NHS to a centrifuge tube, dilute to 1 mL with magnetic bead coupling buffer, and store at 2°C for later use.

[0131] 4.6 Standard formula of EDC solution: According to 1mL standard amount: EDC 0.01g, magnetic bead coupling buffer is made up to 1mL.

[0132] Preparation method of EDC solution: Add 0.01 g of EDC to a centrifuge tube, dilute to 1 mL with magnetic bead coupling buffer, and store at 2°C for later use.

[0133] 4.7 Standard formula of 10% BSA solution: based on 100 mL base volume: BSA 10 g, magnetic bead coupling buffer is made up to 100 mL.

[0134] Preparation method of 10% BSA solution: Add 10 g of BSA to a centrifuge tube, dilute to 100 mL with magnetic bead coupling buffer, and store at 2°C for later use.

[0135] 4.8 Standard formula of magnetic bead storage solution: based on 1000mL base volume: NaH2PO4·2H2O 1.2169g, Na2HPO4·12H2O 4.3693g, sodium chloride 9.00g, BSA 10.00g, Tween-200.5mL and ProClin-3000.5mL. In vitro diagnostic reagents are made up to 1000mL with purified water.

[0136] Preparation method of magnetic bead preservation solution: add 800mL of purified water for in vitro diagnostic reagents into the preparation barrel, weigh sodium chloride, NaH2PO4·2H2O, and Na2HPO4·12H2O in sequence and add them into the preparation barrel, stir at a uniform speed to fully dissolve them, then add BSA, then add Tween-20 and Proclin300, stir at a uniform speed to fully mix them, make up to 1000mL with purified water for in vitro diagnostic reagents, and store at 2°C for later use.

[0137] 4.9 Standard formula of acridinium ester labeling buffer: Based on 1000mL standard amount: NaH2PO4·2H2O 0.83g, Na2HPO4·12H2O 33.92g, sodium chloride 8.77g, Proclin-300 0.5mL, in vitro diagnostic reagent is diluted to 1000mL with purified water.

[0138] Preparation method of acridinium ester labeling buffer: Add 800 mL of purified water for in vitro diagnostic reagents into the preparation barrel, weigh sodium chloride, NaH2PO4·2H2O, and Na2HPO4·12H2O in sequence and add them to the preparation barrel, stir at a uniform speed to fully dissolve them, then add Proclin300, stir at a uniform speed to fully mix them, make up to 1000 mL with purified water for in vitro diagnostic reagents, and store at 2°C for use.

[0139] 4.10 Standard formula of quencher: Based on 10 mL base volume: 1 g of lysine, dilute to 10 mL with acridinium ester labeling buffer.

[0140] Preparation method of quenching agent: Add 1 g of lysine to a centrifuge tube, dilute to 10 mL with acridinium ester labeling buffer, and store at 2°C for later use.

[0141] Example 2 Preparation of a full-scale C-reactive protein (CRP) assay kit (direct chemiluminescence method)

[0142] 1. Prepare magnetic bead working solution

[0143] 1.1 Magnetic bead dilution solution formula

[0144] (1) Magnetic bead dilution solution formula 1:

[0145] NaH2PO4·2H2O 2.2g / L, Na2HPO4·12H2O 1.5g / L, sodium chloride 8.8g / L, alkoxypolyethylene glycol hydroxyethanol 0.9mL / L, sorbitan sesquioleate 0.9mL / L, casein 1.6g / L, glycine 10.5g / L, tryptone 5.3g / L and Proclin3001.2 mL / L.

[0146] (2) Magnetic bead dilution solution formula 2:

[0147] NaH2PO4·2H2O 1.7g / L, Na2HPO4·12H2O 1.2g / L, sodium chloride 9.0g / L, alkoxypolyethylene glycol hydroxyethanol 1.2mL / L, sorbitan sesquioleate 0.7mL / L, casein 1.7g / L, glycine 11.5g / L, tryptone 5.9g / L and Proclin3001.4 mL / L.

[0148] 1.2 The preparation method and steps of magnetic bead diluent are the same as those in Example 1.

[0149] 1.3 The magnetic bead coating method is the same as in Example 1.

[0150] 2. Preparation of acridinium ester working solution

[0151] 2.1 Acridinium ester dilution formula

[0152] (1) Acridinium ester dilution formula 1:

[0153] Components: NaH2PO4·2H2O 3.8 g / L, Na2HPO4·12H2O 2.2 g / L, sodium chloride 7.0 g / L, glycerol 0.9 mL / L, sorbitan oleate 2.5 mL / L, sucrose 0.8 g / L, Tween-80 1.4 mL / L, trypsin 5.3 g / L and Proclin 300 1.9 mL / L.

[0154] (2) Acridinium ester dilution formula 2:

[0155] Components: NaH2PO4·2H2O 3.6 g / L, Na2HPO4·12H2O 2.4 g / L, sodium chloride 6.9 g / L, glycerol 1.0 mL / L, sorbitan oleate 2.4 mL / L, sucrose 0.7 g / L, Tween-80 1.3 mL / L, trypsin 5.6 g / L and Proclin 300 1.5 mL / L.

[0156] 2.2 The preparation method and steps of the acridinium ester dilution are the same as those in Example 1.

[0157] 2.3 The acridinium ester labeling method is the same as in Example 1.

[0158] 3. Preparation of Calibrator Working Solution

[0159] 3.1 Calibrator dilution formula

[0160] (1) Calibrator dilution formula 1:

[0161] NaH2PO4·2H2O 1.9 g / L, Na2HPO4·12H2O 1.4 g / L, sodium chloride 5.7 g / L, Triton X-100 0.9 mL / L, D-sorbitol 0.8 mL / L, sucrose 1.0 g / L and Proclin 300 2.5 mL / L.

[0162] (2) Calibrator dilution formula 2:

[0163] NaH2PO4·2H2O 2.1g / L, Na2HPO4·12H2O 1.3g / L, sodium chloride 5.4g / L, Triton X-100 0.7mL / L, D-sorbitol 1.6mL / L, sucrose 1.5g / L and Proclin300 2.4 mL / L.

[0164] 3.2 The preparation method and steps of the calibration dilution are the same as those in Example 1.

[0165] 3.3 Add the antigen to the calibration diluent at concentrations of 0.50 mg / L, 6.00 mg / L, 30.00 mg / L, and 150.00 mg / L to obtain the calibration working solution.

[0166] 4. Preparation of other reagents

[0167] The reagents and their preparation methods are the same as those in Example 1.

[0168] Example 3 Preparation of Interleukin-6 (IL-6) Assay Kit (Direct Chemiluminescence Method)

[0169] 1. Prepare magnetic bead working solution:

[0170] 1.1 Magnetic bead dilution solution formula

[0171] (1) Magnetic bead dilution solution formula 1:

[0172] NaH2PO4·2H2O 2.2g / L, Na2HPO4·12H2O 1.1g / L, sodium chloride 8.5g / L, alkoxypolyethylene glycol hydroxyethanol 1.0mL / L, sorbitan sesquioleate 0.9mL / L, casein 1.4g / L, glycine 11.5mL / L, tryptone 5.8g / L and Proclin3001.9 mL / L.

[0173] (2) Magnetic bead dilution solution formula 2:

[0174] NaH2PO4·2H2O 2.1g / L, Na2HPO4·12H2O 1.3g / L, sodium chloride 8.0g / L, alkoxypolyethylene glycol hydroxyethanol 0.5mL / L, sorbitan sesquioleate 1.3mL / L, casein 1.6g / L, glycine 11.0mL / L, tryptone 5.4g / L and Proclin3001.2 mL / L.

[0175] 1.2 The preparation method and steps of magnetic bead diluent are the same as those in Example 1.

[0176] 1.3 The magnetic bead coating method is the same as in Example 1.

[0177] 2. Preparation of acridinium ester working solution

[0178] 2.1 Acridinium ester dilution formula

[0179] (1) Acridinium ester dilution formula 1:

[0180] Components: NaH2PO4·2H2O 3.7g / L, Na2HPO4·12H2O 2.5g / L, sodium chloride 7.0g / L, glycerol 0.9mL / L, sorbitan oleate 2.4mL / L, sucrose 0.8g / L, Tween-80 1.5mL / L, tryptone 5.2g / L and Proclin 300 1.6 mL / L

[0181] (2) Acridinium ester dilution formula 2:

[0182] Components: NaH2PO4·2H2O 3.8g / L, Na2HPO4·12H2O 2.4g / L, sodium chloride 6.9g / L, glycerol 1.0mL / L, sorbitan oleate 2.3mL / L, sucrose 0.7g / L, Tween-80 1.4mL / L, tryptone 5.5g / L, Proclin 300 1.2mL / L

[0183] 2.2 The preparation method and steps of the acridinium ester dilution are the same as those in Example 1.

[0184] 2.3 The acridinium ester labeling method is the same as in Example 1.

[0185] 3. Preparation of Calibrator Working Solution

[0186] 3.1 Calibrator dilution formula

[0187] (1) Calibrator dilution formula 1:

[0188] NaH2PO4·2H2O 1.9g / L, Na2HPO4·12H2O 1.4g / L, sodium chloride 5.6g / L, Triton X-100 1.2mL / L, D-sorbitol 1.2mL / L, sucrose 0.8g / L and Proclin300 2.3 mL / L.

[0189] (2) Calibrator dilution formula 2:

[0190] NaH2PO4·2H2O 1.7g / L, Na2HPO4·12H2O 1.5g / L, sodium chloride 5.5g / L, Triton X-100 1.0mL / L, D-sorbitol 1.1mL / L, sucrose 0.9g / L and Proclin300 2.1 mL / L.

[0191] 3.2 The preparation method and steps of the calibration dilution are the same as those in Example 1.

[0192] 3.3 Add the antigen to the calibrator diluent at concentrations of 1.50, 10.00, 100.00, 1000.00, and 5000.00 pg / mL to obtain the calibrator working solution.

[0193] 4. Preparation of other reagents

[0194] The reagents and their preparation methods are the same as those in Example 1.

[0195] Example 4 Preparation of Procalcitonin (PCT) Assay Kit (Direct Chemiluminescence Method)

[0196] 1. Prepare magnetic bead working solution:

[0197] 1.1 Magnetic bead dilution solution formula

[0198] (1) Magnetic bead dilution solution formula 1:

[0199] NaH2PO4·2H2O 2.0g / L, Na2HPO4·12H2O 1.2g / L, sodium chloride 8.5g / L, alkoxypolyethylene hydroxyethanol 0.5mL / L, sorbitan sesquioleate 1.3mL / L, casein 1.7g / L, glycine 10.0mL / L, trypsin 5.6g / L, Proclin3002.5 mL / L.

[0200] (2) Magnetic bead dilution solution formula 2:

[0201] NaH2PO4·2H2O 1.5g / L, Na2HPO4·12H2O 1.5g / L, sodium chloride 8.8g / L, alkoxypolyethylene hydroxyethanol 1.1mL / L, sorbitan sesquioleate 0.8mL / L, casein 1.4g / L, glycine 11.5mL / L, tryptone 5.4g / L and Proclin3001.5 mL / L.

[0202] 1.2 The preparation method and steps of magnetic bead diluent are the same as those in Example 1.

[0203] 1.3 The magnetic bead coating method is the same as in Example 1.

[0204] 2. Preparation of acridinium ester working solution

[0205] 2.1 Acridinium ester dilution formula

[0206] (1) Acridinium ester dilution formula 1:

[0207] NaH2PO4·2H2O 3.8g / L, Na2HPO4·12H2O 2.5g / L, sodium chloride 6.9g / L, glycerol 0.9mL / L, sorbitan oleate 2.3mL / L, sucrose 0.8g / L, Tween-80 1.4mL / L, tryptone 5.4g / L and Proclin 300 1.9mL / L.

[0208] (2) Acridinium ester dilution formula 2:

[0209] NaH2PO4·2H2O 3.7g / L, Na2HPO4·12H2O 2.4g / L, sodium chloride 7.0g / L, glycerol 1.0mL / L, sorbitan oleate 2.4mL / L, sucrose 0.7g / L, Tween-80 1.5mL / L, tryptone 5.5g / L and Proclin 300 1.6mL / L.

[0210] 2.2 The preparation method and steps of the acridinium ester dilution are the same as those in Example 1.

[0211] 2.3 The acridinium ester labeling method is the same as in Example 1.

[0212] 3. Preparation of Calibrator Working Solution

[0213] 3.1 Calibrator dilution formula

[0214] (1) Calibrator dilution formula 1:

[0215] NaH2PO4·2H2O 1.7 g / L, Na2HPO4·12H2O 1.5 g / L, sodium chloride 5.3 g / L, Triton X-100 0.8 mL / L, D-sorbitol 0.4 mL / L, sucrose 0.9 g / L and Proclin 300 1.8 mL / L.

[0216] (2) Calibrator dilution formula 2:

[0217] NaH2PO4·2H2O 2.1g / L, Na2HPO4·12H2O 1.4g / L, sodium chloride 5.5g / L, Triton X-100 1.1mL / L, D-sorbitol 1.0mL / L, sucrose 1.3g / L and Proclin300 1.2 mL / L.

[0218] 3.2 The preparation method and steps of the calibration dilution are the same as those in Example 1.

[0219] 3.3 Add the antigen to the calibrator diluent at concentrations of 0.030, 0.500, 10.000, 50.000, and 100.000 ng / mL to obtain the calibrator working solution.

[0220] 4. Preparation of other reagents

[0221] The reagents and their preparation methods are the same as those in Example 1.

[0222] The performance of the kits prepared in the above Examples 1-4 was verified.

[0223] Verification Example 1

[0224] A performance verification test was performed on the serum amyloid A assay kit (direct chemiluminescence method) prepared in Example 1.

[0225] 1. Experimental operation steps

[0226] (1) Prepare the magnetic bead working solution in the volume corresponding to the number of people to be tested.

[0227] (2) Prepare acridinium ester working solution in a volume corresponding to the number of people to be tested.

[0228] (3) Prepare working solutions of SAA calibrators (0.50, 2.00, 10.00, 50.00, and 200.00 μg / mL) diluted with calibrator diluent, and perform duplicate wells for each titer under each condition. Add 5 μL of the diluted calibrator to each well.

[0229] (4) Detect the luminescence value on the machine. The specific operation is as follows: put the acridinium ester working solution and the magnetic bead working solution into the reagent boat, and put the SAA calibration working solution into the sample rack.

[0230] (5) 80 μL of acridinium ester working solution and magnetic bead working solution were added to the reaction tube using a fully automatic chemiluminescence detector, and then 5 μL of the sample was added and incubated for 10 min.

[0231] (6) Elute the sample solution after incubation for 10 min with the self-prepared cleaning solution.

[0232] (7) Finally, add substrate A first and then substrate B, and directly detect the luminescence value.

[0233] 2. Blank limit

[0234] The main purpose is to verify whether the blank limit of the kit of the present invention meets the requirements.

[0235] 2.1 Inspection methods

[0236] Use zero-concentration calibrator or sample diluent as sample for detection, repeat the measurement 20 times, obtain the RLU value (relative luminescence value) of the 20 measurement results, calculate the mean (M) and standard deviation (SD), and obtain M+2SD. According to the calibration curve equation (EI) of the calibrator provided with the kit, or according to the concentration-chemiluminescence (RLU) value results between the zero-concentration calibrator and the adjacent calibrator, perform two-point regression fitting to obtain a linear equation, substitute the RLU value corresponding to M+2SD into the equation, and calculate the corresponding concentration value, which is LOB. The blank limit should not be greater than 0.10μg / mL.

[0237] 2.2 Acceptability criteria

[0238] Should not be greater than 0.10μg / mL.

[0239] 2.3 Experimental data

[0240] The blank limit test results are shown in Table 3.

[0241] Table 3 Blank limit detection results

[0242]

[0243] From the data in the above table, we can see that the blank limit of the kit is 0.03μg / mL, no more than 0.10μg / mL, and the result meets the requirements.

[0244] 3. Accuracy

[0245] To verify whether the accuracy of the kit of the present invention meets the requirements, the kit is verified by a recovery test.

[0246] 3.1 Inspection methods

[0247] Add serum amyloid A (SAA) sample (A) with a concentration of (100.00±10.00) μg / mL to a low-concentration serum sample or other corresponding matrix (B). The volume of the added sample (A) should not exceed 10% of the total volume (A+B). Perform three parallel measurements and calculate according to formula (1). The results should meet the requirements of 2.2 above.

[0248]

[0249] Where: R—recovery rate; V—volume of sample A solution; V0—volume of sample B solution; c—detection concentration of sample B solution after adding sample A solution; c0—concentration of sample B solution; c s —Concentration of sample A solution.

[0250] 3.2 Acceptability criteria

[0251] The recovery rate should be in the range of 85% to 115%.

[0252] 3.3 Experimental data

[0253] Table 4 Accuracy (recovery rate) test results

[0254]

[0255] From the data in the above table, we can see that the test results of the kit have an accuracy recovery rate between 85.0% and 115.0%, and the accuracy meets the requirements.

[0256] 4. Linear

[0257] Verify whether the linear range of the kit of the present invention meets the requirements.

[0258] 4.1 Inspection methods

[0259] The high-value sample close to the upper limit of the linear interval is diluted to 5 concentrations according to a certain ratio, among which the concentration of the low-value sample is close to the lower limit of the linear interval. Repeat the measurement for each concentration of the sample 3 times, calculate the average value, use the least squares method to perform a straight line fit between the average value of the measured concentration and the theoretical concentration, and calculate the linear correlation coefficient r. The result should meet the requirements of 3.2.

[0260] 4.2 Acceptability criteria

[0261] The linear range of this product is [0.50, 200.00] μg / mL. The linear correlation coefficient r of the kit should not be less than 0.9900 within the linear range.

[0262] 4.3 Test data

[0263] Table 5 Linear detection results

[0264]

[0265] From Table 5 and Figure 1 The data show that the correlation coefficients r of the three batches of test kits are all greater than 0.9900 within the linear range, and the linearity meets the requirements.

[0266] 5. Repeatability

[0267] Repeatability is the test performed when the influencing factors vary the least, that is, by the same operator, the same reagents, the same operating conditions, the same equipment, the same location, and within a short period of time, to verify whether the kit of the present invention meets the repeatability requirements.

[0268] 5.1 Inspection methods

[0269] Repeat the measurement 10 times for working quality control products L and H with concentrations of (100.00±10.00)μg / mL and (5.00±0.50)μg / mL, respectively. Calculate the mean (M) and standard deviation (SD) of 30 measurement results for each concentration sample. Calculate the coefficient of variation (CV) according to formula (2). The result should meet the requirements of 4.3.

[0270] CV=SD / M×100%

[0271] Where: CV is the coefficient of variation; SD is the standard deviation of 10 measurement results; M is the average value of 10 measurement results.

[0272] 5.2 Acceptability criteria

[0273] The coefficient of variation (CV) of the quality control product measurement results should not be greater than 8%.

[0274] 5.3 Test data

[0275] Table 6 Repeatability test data

[0276] Measured value Repeatability Repeatability Measurement 1 99.84 4.95 Measurement 2 97.94 4.93 Measurement 3 102.89 4.95 Measured value 4 101.62 5.14 Measured value 5 97.70 5.11 Measured value 6 98.12 4.92 Measured value 7 100.79 4.95 Measured value 8 102.33 5.06 Measured value 9 98.77 5.17 Measured value 10 101.44 5.00 Mean 100.14 5.02 SD 1.928 0.0945 CV 1.9% 1.9%

[0277] From the data in the above table, we can see that the kit detects working quality control products L and H respectively, and the repeatability of the kit is less than 8%, which meets the requirements.

[0278] 6. Thermal stability

[0279] Determine how different storage conditions affect test results.

[0280] 6.1 Inspection methods

[0281] Place the magnetic bead working solution, acridinium ester working solution and calibrant working solution at 2℃-8℃ and 37℃ for 7 days respectively. At the same time, conduct concentration tests on the complete set of 7 days at 2℃-8℃ and the complete set of 7 days at 37℃. Calculate the concentration drop at 37℃ for 7 days. The results should meet the requirements of 5.2.

[0282] 6.2 Acceptability criteria

[0283] The 7-day drop should not exceed 15%.

[0284] 6.3 Test data

[0285] Table 7 Thermal stability verification results

[0286]

[0287]

[0288] From the data in the above table, it can be seen that the 7-day decrease in the test kit was less than 15%, indicating that the thermal stability of the test kit meets the requirements.

[0289] 7. Clinical sample relevance

[0290] Aims to record the test results of samples from different manufacturers' products and calculate their deviations based on the results.

[0291] 7.1 Inspection methods

[0292] The whole blood was tested according to the serum amyloid A (SAA) assay kit, and the linear correlation coefficient between the two sets of data and Roche Diagnostics was calculated. The correlation coefficient r≥0.975 (or r 2 ≥0.95); use Excel spreadsheet to do t test (paired two-sample analysis of mean value x), P value greater than 0.05, indicating that there is no significant difference between the two groups of samples, and there is consistency; P value less than 0.05, indicating that there is a significant difference between the two groups of samples.

[0293] 7.2 Acceptability criteria

[0294] At the same time, the linear correlation coefficient r≥0.975 (or r 2 ≥0.95) and t-test (P value greater than 0.05), it was confirmed that there was no significant difference between the two groups of samples and they were consistent.

[0295] 7.3 Test data

[0296] Table 8 Sample inspection comparison results

[0297]

[0298]

[0299]

[0300] From Table 8 and Figure 2 The data show that the correlation between the kit of the present invention and the Roche kit is 2The value was 0.9984, and the P value was 0.20, indicating that the kit of the present invention had a better correlation with the Roche kit and had more advantages in clinical detection.

[0301] 8. Sample consistency study

[0302] To determine whether there are differences in test results between different types of samples.

[0303] 8.1 Sample selection

[0304] Basis for sample selection: The samples were collected from patients who underwent cardiovascular and cerebrovascular examinations in a tertiary hospital.

[0305] Sample selection criteria: no age limit, no gender limit; samples should be used immediately after collection and cannot be left at room temperature for a long time. Serum / plasma / whole blood samples should not be stored for more than 2 days at 2℃~8℃, and should not be stored for more than 3 months at -20℃. Samples should not be frozen and thawed more than three times.

[0306] Sample exclusion criteria: insufficient sample size, severe hemolysis or lipemia, and jaundice, etc.; researchers with diseases that the clinical researchers believe are not suitable for participating in this trial.

[0307] 8.2 Inspection methods

[0308] The serum amyloid A (SAA) assay kit (direct chemiluminescence method) of the present invention was used to detect serum, plasma and whole blood, and the linear correlation coefficient of the two groups of data was calculated. The correlation coefficient r≥0.975 (or r 2 ≥0.95); t-test (paired two-sample analysis of mean values) was performed using an Excel spreadsheet. If the P value was greater than 0.05, it indicated that there was no significant difference between the two groups of samples and they were consistent; if the P value was less than 0.05, it indicated that there was a significant difference between the two groups of samples.

[0309] 8.3 Acceptability criteria

[0310] At the same time, the linear correlation coefficient r≥0.975 (or r 2 ≥0.95) and t-test (P value greater than 0.05), it was confirmed that there was no significant difference between the two groups of samples and they were consistent.

[0311] 8.4 Test data

[0312] Table 9 Consistency of samples

[0313]

[0314]

[0315]

[0316] From the data in Table 9 above, it can be seen that the test results of serum and plasma of the kit of the present invention have an r value of 0.9991, and a P value of 0.52; the test results of serum and whole blood have an r value of 0.9992, and a P value of 0.24. It can be considered that the test results of serum, plasma and whole blood samples are consistent, and the kit of the present invention can be used for the detection of three sample types.

[0317] Verification Example 2

[0318] A performance verification test was performed on the full-scale C-reactive protein (CRP) assay kit (direct chemiluminescence method) prepared in Example 2.

[0319] The verification method is the same as that of Verification Example 1.

[0320] The verification results show:

[0321] (1) Blank limit: no more than 0.20 mg / L, all meet the requirements.

[0322] (2) Linearity: In the range of [0.50, 150.00] mg / L, the linear correlation coefficient r is not less than 0.9900; the absolute linear deviation in the interval [0.50, 10.00) mg / L does not exceed ±1.50 mg / L; the relative linear deviation in the interval [10.00, 150.00] mg / L does not exceed ±15.0%.

[0323] (3) Accuracy: The recovery rate is in the range of 85.0% to 115.0%.

[0324] (4) Repeatability: The coefficient of variation (CV) is not greater than 8.0%.

[0325] (5) Thermal stability: The decrease is within 15.0%.

[0326] (6) Clinical sample correlation: r was 0.9987; P value was 0.50.

[0327] (7) Sample consistency: r is 0.9985; P value is 0.34.

[0328] Verification Example 3

[0329] The interleukin 6 (IL-6) assay kit (direct chemiluminescence method) prepared in Example 3 was subjected to a performance verification test.

[0330] The verification method is the same as that of Verification Example 1.

[0331] The verification results are as follows:

[0332] (1) Blank limit: no more than 0.50 pg / mL, all meet the requirements.

[0333] (2) Linearity: In the range of [1.50, 5000.00] pg / mL, the linear correlation coefficient r is not less than 0.9900.

[0334] (3) Accuracy: The recovery rate is in the range of 85.0% to 115.0%.

[0335] (4) Repeatability: The coefficient of variation (CV) is not greater than 8.0%.

[0336] (5) Thermal stability: The decrease is within 15.0%.

[0337] (6) Clinical sample correlation: r was 0.9983; P value was 0.30.

[0338] (7) Sample consistency: r is 0.9986; P value is 0.32.

[0339] Verification Example 4

[0340] A performance verification test was performed on the procalcitonin (PCT) assay kit (direct chemiluminescence method) prepared in Example 4.

[0341] The verification method is the same as that of Verification Example 1.

[0342] The verification results are as follows:

[0343] (1) Blank limit: no more than 0.030 ng / mL, all meet the requirements.

[0344] (2) Linearity: In the range of [0.030, 100.000] ng / mL, the linear correlation coefficient r is not less than 0.9900.

[0345] (3) Accuracy: The recovery rate is in the range of 85.0% to 115.0%.

[0346] (4) Repeatability: The coefficient of variation (CV) is not greater than 8.0%.

[0347] (5) Thermal stability: The decrease is within 15.0%.

[0348] (6) Clinical sample correlation: r was 0.9978; P value was 0.40.

[0349] (7) Sample consistency: r is 0.9982; P value is 0.38.

[0350] The above results show that through the data analysis of the blank limit, linearity, accuracy, repeatability, thermal stability, sample correlation, and sample consistency of the SAA, CRP, IL-6, and PCT assay kits prepared in Examples 1-4, it was found that the blank limit, linearity, accuracy, repeatability, thermal stability, sample correlation, and sample consistency of the four assay kits all met the requirements. This shows that the present invention can provide a simple, sensitive, and highly accurate assay kit for inflammation detection.

[0351] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A diluent for inflammation detection, characterized in that: It comprises a magnetic bead diluent, an acridinium ester diluent and a calibration substance diluent; wherein the magnetic bead diluent comprises the following components: NaH2PO4·2H2O 1.5-2.3 g / L, Na2HPO4·12H2O 1.1-1.5 g / L, sodium chloride 8.0-9.0 g / L, alkoxy polyethylene hydroxyethanol 0.4-1.2 mL / L, sorbitan sesquioleate 0.7-1.4 mL / L, casein 1.4-1.8 g / L, glycine 10.0-12.0 g / L, tryptone 5.3-6.0 g / L and Proclin300 1.2-2.5 mL / L; The acridinium ester diluent comprises the following components: NaH2PO4·2H2O 3.6-3.9 g / L, Na2HPO4·12H2O 2.2-2.5 g / L, sodium chloride 6.9-7.0 g / L, glycerol 0.9-1.0 mL / L, sorbitol oleate 2.3-2.5 mL / L, sucrose 0.7-0.9 g / L, Tween-80 1.3-1.5 mL / L, tryptone 5.2-5.6 g / L and Proclin 300 1.2-2.5 mL / L; The calibration diluent comprises the following components: NaH2PO4·2H2O 1.5-2.2 g / L, Na2HPO4·12H2O 1.3-1.5 g / L, sodium chloride 5.3-5.7 g / L, Triton X-100 0.6-1.2 mL / L, D-sorbitol 0.4-1.6 g / L, sucrose 0.8-1.5 g / L and Proclin 300 1.2-2.5 mL / L.

2. A method for preparing the diluent according to claim 1, characterized in that: The method comprises preparing a magnetic bead diluent, an acridinium ester diluent and a calibrant diluent respectively as follows: (1) The method for preparing the magnetic bead diluent comprises the following steps: According to the formula of the magnetic bead diluent, weigh each component for later use; Add NaH2PO4·2H2O, Na2HPO4·12H2O and sodium chloride to purified water in sequence, stir to fully dissolve, and then adjust the pH to 7.2-7.5 to obtain an intermediate solution; Adding alkoxy polyethylene hydroxyethanol, sorbitan sesquioleate, casein, Proclin 300, glycine and tryptone to the intermediate solution in sequence and mixing them evenly; Dilute to volume with purified water to obtain the magnetic bead dilution solution; (2) The preparation method of the acridinium ester dilution comprises the following steps: According to the formula of the acridinium ester diluent, weigh each component for later use; Add NaH2PO4·2H2O, Na2HPO4·12H2O and sodium chloride to purified water in sequence, stir to fully dissolve, and then adjust the pH to 7.5-7.8 to obtain an intermediate solution; Add glycerol, sorbitan oleate, sucrose, Tween-80, tryptone and Proclin 300 to the intermediate solution in sequence and mix well; Dilute to volume with purified water to obtain the acridinium ester dilution solution; (3) The preparation method of the calibration dilution comprises the following steps: According to the formula of the calibration diluent, weigh each component for later use; To purified water for in vitro diagnostic reagents, NaH2PO4·2H2O, Na2HPO4·12H2O and sodium chloride were sequentially added, stirred to fully dissolve, and then the pH was adjusted to 7.5-7.8 to obtain an intermediate solution; Adding Triton X-100, D-sorbitol, sucrose and Proclin 300 to the intermediate solution in sequence and mixing well; The in vitro diagnostic reagent is diluted to volume with purified water to obtain the calibrator dilution solution.

3. Use of the diluent as claimed in claim 1 in preparing a kit for detecting inflammation by direct chemiluminescence method.

4. The use according to claim 3, characterized in that The direct chemiluminescence method for detecting inflammation kit is a kit for detecting inflammation markers using the direct chemiluminescence method, and the inflammation markers include serum amyloid A, full-scale C-reactive protein, interleukin 6 and procalcitonin.

5. A kit for detecting inflammation by direct chemiluminescence, characterized in that: Comprising the diluent according to claim 1.

6. The kit according to claim 5, characterized in that The diluent is used in the form of a working solution when in use, wherein the magnetic bead diluent is prepared by mixing the coated magnetic bead-coated antibody with the magnetic bead diluent at a volume ratio of 1:25, 1:50 or 1:100 to obtain a magnetic bead working solution; the acridinium ester diluent is prepared by mixing the acridinium ester diluent with the acridinium ester-labeled antibody at a volume ratio of 1:100, 1:200 or 1:400 to obtain an acridinium ester working solution; the calibrator diluent is prepared by diluting the calibrator diluent with the antigen according to a concentration in the linear range of [0.0015-200000] ng / mL to obtain a calibrator working solution.

7. The kit according to claim 5, characterized in that The kit also includes a cleaning solution concentrate, a substrate A and a substrate B.

8. The kit according to claim 5, characterized in that The cleaning solution concentrate includes disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, Tween-20 and Proclin300; the substrate A is an acidic solution containing H2O2; and the substrate B is an alkaline solution containing Triton X-100.

Citation Information

Cited By

  • Biological sample diluent and application of detection method thereof in immunodetection kit

    CN119716092A

  • Application of Biological Sample Diluent and Its Detection Method in Immunoassay Kit

    CN119716092B